MONTREAL and KIEL, Germany, September 14 /PRNewswire/ -- Working in
collaboration with Kiel University, researchers at the Kiel- based Collagen
Research Institute (CRI) have demonstrated the stimulating effect of special
bioactive collagen peptides (FORTIGEL(R)) in the context of cell experiments.
Last weekend the CRI presented its research findings at the congress of the
Osteoarthritis Research Society International (OARSI) in Montreal. The
investigations of the CRI provide an explanation for the findings of a joint
clinical trial carried out by
In cooperation with Kiel University the CRI researchers applied molecular-biology and protein-chemistry analysis methods directly to the cells in order to demonstrate the stimulating effect of FORTIGEL(R). Developed by GELITA AG, this product contains a special combination of high-purity bioactive collagen peptides. "In our investigations we showed that - alongside the synthesis of Type II collagen - FORTIGEL(R) induces the increased production of aggrecan, a special proteoglycan which is of central importance to the cartilage function," explains Dr. Steffen Oesser, Director of the CRI. This provides experimental proof that the application of bioactive collagen peptides stimulates the renewed synthesis of the extracellular cartilage matrix.
Cell experiment underpins the
The cell-based experiments of the CRI confirm the findings of a clinical
trial conducted by the
The double-blinded, placebo-controlled
To analyze the structural changes in the cartilage tissue the
Treatment of osteoarthritis
"The targeted manipulation of the cartilage metabolism opens up new possibilities for the treatment and prevention of osteoarthritis," emphasizes Dr. Oesser. Unlike analgesic and antirheumatic drugs, which merely alleviate the symptoms and effects, FORTIGEL(R) now offers the potential for an alimentary, causal therapy.
Worldwide approximately 135 million people suffer from osteoarthritis. Experts predict a rapid rise in this figure - above all in the industrialized nations. The prevention of arthritic diseases enjoys top priority, due not least to the high costs incurred by the healthcare systems.
Based in Kiel/Germany, the Collagen Research Institute (CRI) was established in 2003 as an independent research organization. The institute's activities centre on degenerative changes to the connective tissue and the development of complementary and alternative therapies in the area of osteoarthritis, osteoporosis and wound healing. Since its establishment CRI has devoted special attention to investigating the effects of collagen peptides on the extracellular matrix of the articular cartilage.
Collagen Research Institute Dr. Steffen Oesser Tel. +49-(0)431-56-06-610 Fax +49-(0)431-56-06-613 email@example.com
|SOURCE Collagen Research Institute|
Copyright©2009 PR Newswire.
All rights reserved